Difficulty: Medium
Average Score: 88%
Practice
Which of the following benzodiazepines is expected to cause the least amount of adverse effects in the elderly?
Correct answer
D
Rationale
In the context of CNS stimulants drugs pharmacology, choosing the benzodiazepine that causes the least amount of adverse effects in the elderly is crucial due to the increased sensitivity and susceptibility of this population to drug-related complications. In this case, the correct answer is D) Oxazepam.
Oxazepam is preferred in the elderly population due to its pharmacokinetic profile. It undergoes minimal hepatic metabolism, leading to fewer drug interactions and a lower risk of accumulation in the elderly who may have compromised liver function. This reduced metabolism also results in a decreased likelihood of active metabolites contributing to adverse effects.
On the other hand, options A, B, and C (Chlordiazepoxide, Diazepam, and Fluazepam) are metabolized by the liver to active metabolites that can accumulate in the elderly, leading to prolonged sedation, cognitive impairment, and increased risk of falls and fractures. These benzodiazepines also have a higher potential for drug interactions due to their hepatic metabolism, posing a greater risk of adverse effects in older adults.
Educationally, understanding the pharmacokinetic differences among benzodiazepines is essential for healthcare providers working with elderly patients. By selecting medications like Oxazepam with a more favorable safety profile in this population, healthcare professionals can minimize the risk of adverse effects and optimize therapeutic outcomes when managing conditions that require CNS stimulant drugs. This knowledge empowers prescribers to make informed decisions tailored to the specific needs of elderly patients, promoting safe and effective pharmacotherapy practices.
Oxazepam is preferred in the elderly population due to its pharmacokinetic profile. It undergoes minimal hepatic metabolism, leading to fewer drug interactions and a lower risk of accumulation in the elderly who may have compromised liver function. This reduced metabolism also results in a decreased likelihood of active metabolites contributing to adverse effects.
On the other hand, options A, B, and C (Chlordiazepoxide, Diazepam, and Fluazepam) are metabolized by the liver to active metabolites that can accumulate in the elderly, leading to prolonged sedation, cognitive impairment, and increased risk of falls and fractures. These benzodiazepines also have a higher potential for drug interactions due to their hepatic metabolism, posing a greater risk of adverse effects in older adults.
Educationally, understanding the pharmacokinetic differences among benzodiazepines is essential for healthcare providers working with elderly patients. By selecting medications like Oxazepam with a more favorable safety profile in this population, healthcare professionals can minimize the risk of adverse effects and optimize therapeutic outcomes when managing conditions that require CNS stimulant drugs. This knowledge empowers prescribers to make informed decisions tailored to the specific needs of elderly patients, promoting safe and effective pharmacotherapy practices.